Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BHV-1300

Other · developed by Biohaven

Phase 3 Most advanced trial

BHVN Developer

1 Registered trials

What is BHV-1300?

BHV-1300 is an investigational drug studied in Graves Disease.

At a glance

Drug type: Other
Therapy area: Endocrine
Developer: Biohaven (BHVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07661056	Phase 3	Graves Disease	Recruiting	BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Graves Disease

More from Biohaven

BHV-1400 Phase 3 BHV-1530 Phase 1 BHV-2100 Phase 2 BHV-700 Phase 1 BHV-7000 Phase 2/3 BHV-8000 Phase 2/3 PBI-410 Phase 1/2 Talditercept Alfa Phase 3 Troriluzole Phase 3 Verdiperstat Phase 3

Sources

ClinicalTrials.gov NCT07661056

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.

Follow BHVN, the company behind BHV-1300

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z